Sanofi drug Dupixent wins FDA approval to treat asthma

Sanofi drug Dupixent wins FDA approval to treat asthma

(Reuters) – France’s Sanofi SA said on Friday eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy in patients with two types of asthma. Dupixent, co-developed with U.S.-based Regeneron, received approval to treat patients with eosinophilic asthma and those dependent on anti-inflammatory steroids. The drug acts by…

Continue Reading